Other Studies on Oral 131I Administration for Dialysis Patients
| Study | Summary | Similarities to case 3 | Differences from case 3 |
|---|---|---|---|
| Vermandel et al. ( 25 ) | Six ESRD patients were administered reduced RAI formulas to treat thyroid cancer; bone marrow toxicity was analyzed to define optimal dosimetry | ESRD; successful removal of 131I remnants | Dosimetry used to minimize toxicity |
| Magné et al. ( 21 ) | Hemodialysis was safe and effective during oral 131I RAI treatment of differentiated thyroid carcinoma | ESRD; metastases; successful excretion | Papillary thyroid carcinoma; metastases in 9 of 16 cervical nodes |
| Shields et al. ( 11 ) | Safe hemodialysis techniques and protocol were shared for minimizing radiation risks and maintaining RAI treatment | ESRD; successful excretion; patient interaction minimized | Not applicable |
| Bhat et al. ( 17 ) | Radioactive ablation in ESRD patient after complete thyroidectomy remained successful 4 y later | ESRD; history of hypertension, diagnostic prescan with 123I | Goiter; presented with shortness of breath after left thyroidectomy |
ESRD = end-stage renal disease.